Aaron Davis
Director/Board Member presso ODONATE, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Christopher Fuglesang | M | 56 |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California.
MVA Investors LLC
MVA Investors LLC Financial ConglomeratesFinance Part of Tavistock Group, Inc., MVA Investors LLC is a private company that provides investment services. The company is based in San Diego, CA. The CEO of the company is Aaron I. Davis.
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA.
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA.
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | 19 anni |
Henrik Ørum | M | - |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE.
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | 8 anni |
Shalom Jacobovitz | M | 62 |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE.
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | 6 anni |
Lesley Calhoun | F | 58 |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | 3 anni |
Michel Detheux | M | 57 | 12 anni | |
Craig Johnson | M | 62 | 11 anni | |
Mace Rothenberg | M | 67 |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | 3 anni |
Barbara Weber | M | 67 |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | 7 anni |
Daphne Karydas | F | 49 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 3 anni |
Douglas John Barry | M | 54 | 3 anni | |
Sandra Ramos-Alves | F | - | - | |
Zack Malkin | M | - | - | |
Robert Iannone | M | 57 | 3 anni | |
Kevin Tang | M | 57 | 11 anni | |
Tony Ho | M | 58 | 3 anni | |
Robert J. Sims | M | - |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Andrew Ellis | M | 41 |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 6 anni |
Kimberly McCutcheon Jablonski | F | - | - | |
David Lee | M | - | 1 anni | |
Ryan Cole | M | - | 10 anni | |
Dominik Naczynski | M | - |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 10 anni |
Michael Hearne | M | 61 | 9 anni | |
John Ketchum | M | - | 1 anni | |
Lorence Kim | M | 49 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Abbie Celniker | M | 65 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Ann Rhoads | F | 58 | 4 anni | |
Carole Nüchterlein | F | 63 |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE.
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | 7 anni |
Tim van Hauwermeiren | M | 52 | 6 anni | |
David Hallal | M | 57 | 6 anni | |
Christian Gagel | M | - | 3 anni | |
Philippe Brantegem | M | - | 4 anni | |
Adam Crystal | M | 47 | 1 anni | |
Sophia Park | F | - | - | |
Ali Baker | F | - |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 2 anni |
Dimitris Papoutsakis | M | - |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | - |
Kevin Christal | M | - |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | 6 anni |
Arnav Mehta | M | - |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 3 anni |
Adi Osovsky | F | - | 3 anni | |
John Ross | M | - | 4 anni | |
Joy Bruce | M | - | 2 anni | |
Matthew Gall | M | 47 | 4 anni | |
Norman Zhou | M | - |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 8 anni |
Sam Gerson | M | - |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 6 anni |
Malte Peters | M | 61 |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | 6 anni |
Michael L. Meyers | M | 74 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 1 anni |
Jill DeSimone | F | 68 | - | |
Reid Huber | M | 52 |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | 5 anni |
Jakob Loven | M | 46 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Konstantina Katcheves | F | - | - | |
Daniella Beckman | F | 45 |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | 5 anni |
Siddarth Subramony | M | 37 |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 6 anni |
Yvonne McGrath | M | 50 | 4 anni | |
Steven Pfeiffer | M | 48 | 8 anni | |
Cary Pfeffer | M | 61 |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | - |
James Avery | M | 59 |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | 5 anni |
Matthew Call | M | 51 | 5 anni | |
Mike Pellini | M | - |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA. | - |
Bronson Crouch | M | 51 | - | |
Jigar Raythatha | M | 47 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | 1 anni |
Steven Paul | M | 73 |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Avanish Vellanki | M | 49 | 7 anni | |
Charles Baum | M | 65 | 12 anni | |
Rodney Lappe | M | 69 | 7 anni | |
Vickie Reed | F | 62 | 9 anni | |
Nelson Cabatuan | M | 47 | - | |
Franklin Berger | M | 74 | 4 anni | |
Jeffrey Vacirca | M | 55 | 3 anni | |
Peter Radovich | M | 46 | 6 anni | |
Daniel Faga | M | 44 | 1 anni | |
Derek DiRocco | M | 43 | 3 anni | |
Temre Johnson | M | - | 5 anni | |
Shubh Goel | M | 51 | - | |
Valerie L. Legagneur | F | 50 | - | |
Gorjan Hrustanovic | M | 35 | 6 anni | |
Stefani Wolff | F | 62 | 3 anni | |
Maya Martinez-Davis | F | 54 | 6 anni | |
Vince Marino | M | - |
Tavistock Group, Inc. (United States)
Tavistock Group, Inc. (United States) Financial ConglomeratesFinance Part of Tavistock Group, Inc., the private company is based in Windermere, FL. Tavistock Group, Inc. (United States) is an international private investment family office that invests in various sectors such as real estate, hotels, restaurants, sports, energy, retail, biotechnology, agriculture, and finance. The company brings capital, experience, flexibility, and a broad base to their investments. The company was founded on the philosophy of striving for excellence in everything they do and values long-term relationships with their investments around the world. | 7 anni |
Reena Desai | F | - | - | |
Detlev Biniszkiewicz | M | 56 | 5 anni | |
Laura Douglass | F | 59 | - | |
Carol Gallagher | M | 59 | 1 anni | |
Shalini Sharp | F | 49 | 3 anni | |
Faheem Hasnain | M | 65 | 5 anni | |
Bruce Carter | M | 80 | 8 anni | |
Henry Fuchs | M | 66 | 11 anni | |
Michael Grey | M | 71 | 7 anni | |
John McKearn | M | 70 |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | 5 anni |
Julie Cherrington | M | 66 | 5 anni | |
Matt Roden | M | 53 | 3 anni | |
Tran Nguyen | M | 50 | 6 anni | |
Neil Reisman | M | 62 | 1 anni | |
John G. Lemkey | M | 43 | 7 anni | |
John Moriarty | M | 56 | - | |
David Meek | M | 59 | 2 anni | |
Aaron Ondrey | M | 48 | 2 anni | |
Michael E. Paolucci | M | 64 | 2 anni | |
Laurie Stelzer | F | 56 | 1 anni | |
Richard Bryce | M | 66 | 2 anni | |
Jamie A. Donadio | M | 48 | 7 anni | |
Kolbot By | M | - | 1 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Aaron Davis
- Contatti personali